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Summary
Background Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the 
skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment 
with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly 
effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and 
tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks 
(RC8) with that of RS8 for treatment of early Buruli ulcer lesions.
Methods We did an open-label, non-inferiority, randomised (1:1 with blocks of six), multicentre, phase 3 clinical trial 
comparing fully oral RC8 with RS8 in patients with early, limited Buruli ulcer lesions. There were four trial sites in 
hospitals in Ghana (Agogo, Tepa, Nkawie, Dunkwa) and one in Benin (Pobè). Participants were included if they were 
aged 5 years or older and had typical Buruli ulcer with no more than one lesion (caterories I and II) no larger than 
10 cm in diameter. The trial was open label, and neither the investigators who took measurements of the lesions nor 
the attending doctors were masked to treatment assignment. The primary clinical endpoint was lesion healing (ie, full 
epithelialisation or stable scar) without recurrence at 52 weeks after start of antimicrobial therapy. The primary 
endpoint and safety were assessed in the intention-to-treat population. A sample size of 332 participants was calculated 
to detect inferiority of RC8 by a margin of 12%. This study was registered with ClinicalTrials.gov, NCT01659437.
Findings Between Jan 1, 2013, and Dec 31, 2017, participants were recruited to the trial. We stopped recruitment after 
310 participants. Median age of participants was 14 years (IQR 10–29) and 153 (52%) were female. 297 patients had 
PCR-confirmed Buruli ulcer; 151 (51%) were assigned to RS8 treatment, and 146 (49%) received oral RC8 treatment. In 
the RS8 group, lesions healed in 144 (95%, 95% CI 91 to 98) of 151 patients, whereas lesions healed in 140 (96%, 
91 to 99) of 146 patients in the RC8 group. The difference in proportion, –0·5% (–5·2 to 4·2), was not significantly 
greater than zero (p=0·59), showing that RC8 treatment is non-inferior to RS8 treatment for lesion healing at 52 weeks. 
Treatment-related adverse events were recorded in 20 (13%) patients receiving RS8 and in nine (7%) patients receiving 
RC8. Most adverse events were grade 1–2, but one (1%) patient receiving RS8 developed serious ototoxicity and ended 
treatment after 6 weeks. No patients needed surgical resection. Four patients (two in each study group) had skin grafts.
Interpretation Fully oral RC8 regimen was non-inferior to RS8 for treatment of early, limited Buruli ulcer and was 
associated with fewer adverse events. Therefore, we propose that fully oral RC8 should be the preferred therapy for 
early, limited lesions of Buruli ulcer.
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Introduction
Buruli ulcer, a necrotising skin disease caused by 
Mycobacterium ulcerans, is one of the 20 neglected tropical 
diseases.1 In Africa, the disease was first identified and 
described near the Nile River in the former Buruli county 
in Uganda. Buruli ulcer has been reported in at least 
33 countries,2 with most cases occurring in west Africa. 
Sporadic cases occur in many locations in central America 
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and South America (notably in French Guyana) and in 
Japan and the western Pacific region.3 Prevalence of the 
disease is highly variable, ranging from 3·1 to 30·7 cases 
per 100 000 population.4 Even in endemic areas, prev­
alence is highly focal and varies considerably in space and 
time.5 In sub­Saharan Africa, the median age of new 
cases is around 20 years,6,7 whereas in the temperate 
climate of southeast Australia, the median age is around 
60 years.8,9
Before 2005, surgery was the mainstay of treatment, 
which often required excision with a 1–2 cm rim of 
apparently healthy skin, followed by skin grafting. 
A proof­of­principle study in Ghana showed the efficacy 
of the combination of oral rifampicin 10 mg/kg plus 
streptomycin 15 mg/kg (intramuscularly) for 8 weeks 
(RS8) to kill M ulcerans in early, limited (lesions of 10 cm 
or less cross­sectional diameter) Buruli ulcer disease.10 
WHO subsequently issued provisional guidelines for 
RS8 as the standard treatment in highly burdened 
regions in Africa. Early antimicrobial treatment gives 
excellent outcomes, but when treatment is delayed or 
disease is diagnosed late, severe morbidity, permanent 
disability, and social stigma with loss of productivity and 
school drop­out can ensue.11–13 RS8 has proven effective 
in healing all forms of Buruli ulcer disease and has led 
to a reduction of the recurrence rate from between 
6% and 47% after surgery alone, to negligible after 
antimicrobial treatment.14,15 However, daily streptomycin 
injections are painful and potentially toxic16 and this 
toxicity, in turn, jeopardises early reporting and compli­
ance with therapy. Patients have to travel long distances 
to health facilities for daily treatment; hence, fully oral 
treatment is needed.
In mouse footpad studies comparing the standard 
RS8 therapy with rifamycins and other antimicrobials, 
clarithromycin (a macrolide drug) was deemed a suitable 
replacement for streptomycin, and treatment of these 
experimental animals with fully oral rifampicin 10 mg/kg 
plus clarith romycin 15 mg/kg for 8 weeks (RC8) was as 
effective as RS8.17,18 Studies in humans have shown that 
switching from streptomycin to clarithromycin after 
4 weeks15 or after 2 weeks19 yielded similar efficacy to RS8 
therapy. In addition, a pilot study in Benin provided 
initial data suggesting the efficacy of fully oral RC8 
treatment,20 but no direct comparison was made between 
RS8 and RC8, and some patients with larger lesions still 
needed surgical treatment. Here, we report results from 
a clinical study designed to compare the efficacy and 
tolerability of RC8 with that of RS8 for treatment of early 
Buruli ulcer lesions.
Methods
Study design and participants
We did an open­label, randomised, multicentre, phase 3 
clinical trial with a non­inferiority design. The study 
adhered to the Consolidated Standards for the Reporting 
of Randomized Controlled Trials guide lines.21 The study 
was done in four hospitals in south Ghana (Agogo 
Presbyterian Hospital, Tepa Goverment Hospital, Nkawie 
Government Hospital, and Dunkwa Government 
Hospital) and in one hospital in south Benin (Pobè 
Health Centre).22
Trained community health workers referred patients 
clinically diagnosed with M ulcerans disease for possible 
enrolment, combining active and passive case finding 
approaches.23,24 Patients were included in the study if 
Research in context
Evidence before this study
We searched PubMed from database inception until 
Dec 31, 2011, without language restrictions for clinical trials 
and randomised clinical trials using the search string: (“Buruli” 
OR “Mycobacterium” AND “ulcerans”) AND (“antimycobact*” 
OR “antimicrob*” OR “antibiotic*”) AND “treatment”. 
The standard treatment for Buruli ulcer is combination 
antibiotic therapy comprising intramuscular streptomycin and 
oral rifampicin daily for 8 weeks. Streptomycin injections are 
painful and can cause ototoxicity. A systematic review found 
case reports and observational cohort studies that showed the 
potential effect of fully oral antibiotic combinations for the 
treatment of Buruli ulcer. No previous trials in humans have 
tested the efficacy of a fully oral antibiotic regimen.
Added value of this study
This open-label, randomised, controlled, phase 3 trial evaluated 
the efficacy of a fully oral treatment with once daily rifampicin 
and clarithromycin 15 mg/kg extended release compared with 
standard of care using a non-inferiority design. Rates of healing 
of Buruli lesions were similar in both groups. Treatment-related 
adverse events, particularly otovestibular toxicity, were more 
common in patients receiving combined rifampicin and 
streptomycin than in patients receiving combined rifampicin 
and clarithromycin. In rural African regions endemic for Buruli 
ulcer, access to health care is difficult; hospital-based care and 
injections impose physical and financial barriers. Fully oral 
treatment provides the opportunity of decentralised care with 
optimal chances of healing, and an excellent safety profile.
Implications of all the available evidence
A fully oral treatment comprising rifampicin and clarithromycin 
is non-inferior to streptomycin–rifampicin in healing of early, 
limited Buruli ulcer lesions and is associated with a better safety 
profile. Fully oral rifampicin and clarith romycin can be provided 
as decentralised care, and should be considered the new 
standard of care for patients with Buruli ulcer disease; patients 
with limited lesions given the treatment have an excellent 
chance of healing without additional surgery.
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they were aged 5 years or older and had clinically 
identified typical Buruli ulcer with no more than one 
lesion that was a maximum 10 cm in diameter. Exclusion 
criteria were children younger than 5 years, individuals 
with lesions bigger than 10 cm in diameter, pregnancy, 
drug intolerance, renal or hepatic impairment, HIV 
infection, or previous treatment with trial medication.
The protocol and consent forms were approved by the 
Ethics Review Committee of the Ghana Health Service 
(GHS­ERC01/03/11) and Benin (N°108/MS/DC/SGM/
DFRS/CNPERS/SA). Ethics approval was also granted 
by the WHO Ethics Review Committee (RPC443), and 
the University Medical Centre Groningen Ethics Review 
Board reviewed the protocol (M11.097746). Written and 
verbal informed consent was obtained from all partici­
pants aged 12 years or older, and from parents, caretakers, 
or legal representatives of participants younger than 
18 years. All staff involved in the study received formal 
training in good clinical practice.
Randomisation and masking
Eligible participants were randomly assigned (1:1) to 
receive RS8 or RC8; the dosing schedule is provided 
in the appendix (p 4). Randomisation was done with 
minimisation for study site and type of lesion (ulceration 
or non­ulceration). The randomisation sequence was 
computer­generated with blocks of six for each centre and 
concealed in opaque envelopes. Neither the investigators 
who took measurements of the lesions nor the attending 
doctors were masked to treatment assignment. As healing 
could be anticipated to occur at any timepoint in any of 
the study sites, and as the study teams in each centre not 
only assessed the image but also had the opportunity to 
palpate the lesion, and therefore had better assessment 
tools to verify healing (ie, full epithelialisation), we 
recorded the assessment by the study teams aware of 
treatment allocation as the primary endpoint. To evaluate 
whether this unmasked assessment of the primary 
endpoint (ie, healing) could be biased, we invited an 
independent technical expert panel masked to treatment 
assignment to review a sample of individual image sets. 
A study monitor (NFS) assessed data entries. Diagnostic 
uncertainties and adverse events were discussed with the 
(co­)principal investigators (TSvdW, ROP, JR) and the 
sponsor, using an electronic web­based platform. Annual 
auditing trips to the study sites were made. All data were 
entered on paper and uploaded into OpenClinica. The 
electronic data files were collected and managed by the 
Drugs for Neglected Diseases initiative, Africa Regional 
Office, Nairobi, Kenya.
Procedures
After participants had given informed consent, demo­
graphic details, clinical information, and blood samples 
were obtained. Pregnancy tests were done in female 
participants aged 10 years and older after pre­test coun­
selling, and hearing tests were done for all participants 
(AS208 portable equipment, Interacoustics, Assens, 
Denmark) to obtain baseline audiometry data. HIV 
antibody tests (Alere Determine HIV 1/2 Kit, Alere, 
Waltham, MA, USA) were done after pre­test counselling.
The dimensions and aspect of lesions were docu­
mented by taking digital photographs to measure the 
surface area of lesions over time. An imaging system 
was used to compute the lesion size at baseline and 
during each follow­up visit (ARANZ, Wellington, 
New Zealand).
Diagnosis of Buruli ulcer was confirmed by quantitative 
PCR amplication of the IS2404 sequence from fine­
needle aspirates or swab samples of lesions.25 In Ghana, 
samples were transported from study sites to the Kumasi 
Centre for Collaborative Research in Kumasi, Ghana, for 
analysis. Samples from Pobè Health Centre in Benin 
were initially all analysed in Centre de recherche en 
cancérologie et immunologie Nantes­Angers, Angers, 
France; subsequently, samples were also analysed in 
Pobè (with confirmation in Angers). All laboratories par­
ticipated in an external quality assessment programme 
done by the WHO reference laboratory in the Institute of 
Tropical Medicine, Antwerp, Belgium.26
In the Ghanaian study sites, most patients were treated 
as outpatients. After assessment and initiation of treat­
ment at the hospital, at the Pobè Health Centre in Benin, 
all patients recruited were treated as inpatients, in line 
with routine practice. Patients in Ghana who were treated 
as outpatients were given medication in weekly batches to 
take to the nearest health facility where they received 
directly observed therapy for the subsequent days, 
with daily wound care. Participants’ travel costs were 
reimbursed, and small meals were given to study 
participants. For ulcers with active discharge, absorptive 
dressing material (Beier Drawtex Healthcare, Pinetown, 
South Africa) was applied to maintain a moist environment 
for wound healing. When lesions were non­exuding, 
vaseline gauze was applied. Short stretch bandages were 
used to prevent lymphoedema. Only participants who had 
lesions involving joints or who resided in distant villages 
were admitted to hospital in Ghana. The health­care 
worker who observed the treatment recorded drug intake 
on the study form. The adherence to treatment according 
to treatment allocation was primarily assessed from the 
study file entries. In Ghana, a system to fully supervise 
treatment was implemented involving a network of 
village health workers and nurses, whereas the co­
principal investigator and the study monitor in Ghana 
verified adherence personally on a regular basis. In the 
study centre in Benin, all patients were admitted for the 
time of treatment, allowing directly supervised treatment 
throughout. Each study site had dedicated trained staff 
for wound care and for prevention of disability.
Rifampicin tablets and extended release clarithromycin 
were shipped to the trial sites. The pharmacists at Agogo 
Presbyterian Hospital and Pobè Health Centre were 
responsible for storage of the trial medication.
See Online for appendix
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Participants were followed up once every 2 weeks 
during the first 8 weeks and then monthly for 12 months. 
At review visits, clinical assessments included obtaining 
photographs of lesions. In addition, safety outcomes were 
assessed every 4 weeks by measuring liver, kidney, and 
auditory tests in all participants. Female participants aged 
10 years and older received pregnancy tests at weeks 2, 4, 
and 6.
Lesions that did not heal were measured and photo­
graphed. Treatment failure was recorded if the lesion had 
not healed by week 52 or if the lesion had recurred within 
the year. Removal of necrosis and slough, along with skin 
grafting, were part of normal care. Requirements for these 
procedures were not considered evidence of treatment 
failure, as per protocol. Daily dressing changes were 
provided if wounds were discharging excessively.
Outcomes
The primary clinical endpoint was lesion healing (ie, full 
epithelialisation, or stable scar) without recurrence at 
52 weeks after start of antimicrobial therapy. Secondary 
objectives were: (1) to compare the recurrence rates 
within 12 months of treatment initiation between the 
RC8 and RS8 groups; (2) to compare the treatment failure 
rates within 12 months of treatment initiation between 
the RC8 and RS8 groups; (3) to compare the incidences of 
paradoxical response, defined as increase of surface area 
of a lesion by more than 20% compared with a previous 
measurement, after initial reduction in lesion size,27 
within 12 months of treatment initiation between the 
RC8 and RS8 groups; (4) to assess whether lesion healing 
depends on lesion category (I or II ≤10 cm in diameter) 
and lesion type (nodule, plaque, ulcer, or oedema) and 
treatment regimen, in terms of lesion sizes (surface area), 
time to complete lesion healing, healing without 
additional surgery or relapse, type of adjunctive surgical 
therapy, and time from treatment initiation to surgery; 
(5) to compare the rates of residual functional limitations 
at 12 months following treatment with the two antibiotic 
regimens (RC8 and RS8) and lesion category (I or II) and 
lesion type (nodule, plaque, oedema, or ulcer); (6) to com­
pare the compliance rates in patients given RC8 and 
RS8 regimens; (7) to compare the inci dences and relative 
risk of all adverse events, including treatment­related 
adverse events, serious adverse events, and grade 3–4 
toxicity in patients given RC8 and RS8 regimens; and 
(8) to compare treatment discontinuation rates in patients 
given RC8 and RS8 regimens. If a serious adverse event 
was suspected or detected, we shared this information 
with all investi gators and members of the data safety 
monitoring board, using the web­based platform. Safety 
outcomes were separately analysed and compared 
between study groups. For hearing loss, we used a 
threshold increase of more than 25 dB.
Statistical analysis
Assuming an efficacy of 96% for standard RS8 treat­
ment,15 the sample size needed to detect inferiority of the 
experimental RC8 treatment by a margin of 12% for oral 
treatment was calculated to be 332 study participants 
with PCR­confirmed Buruli ulcer. Baseline comparisons of 
clinical and demographic characteristics according to 
study group allocation were done using Student’s t test 
for parametric continuous data or the Mann­Whitney 
U­test for non­parametric data. Categorical data were 
compared using χ² tests. The analysis was by intention to 
treat using a one­sided t test for the primary outcome. 
Time to healing was analysed by a Cox proportional 
hazards model to assess the cumulative probability of 
healing. Hazards ratios were reported with 95% CIs. We 
used Stata version 15 for analyses. A data safety moni­
toring board was used. This study was registered with 
clinicaltrials.gov, NCT01659437.
Role of the funding source
The sponsor and the donors had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. ROP, JR, RO, MOO, YS and 
TSvdW had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Participants were recruited to the trial between 
Jan 1, 2013, and Dec 31, 2017. We had initially planned a Figure 1: Trial profile
154 allocated and received 
clarithromycin and rifampicin 
 
146 analysed 
4 lost to follow-up (censored)
443 individuals assessed for eligibility
310 randomly assigned
133 ineligible
 66 lesion too large
 31 <20 kg or <5 years old
 10 HIV infection
   9 previous treatment
   7 pregnant
   5 multiple lesions 
   3 osteomyelitis
   1 lesion at critical site
   1 PCR was negative
156 allocated and received 
streptomycin and rifampicin 
151 analysed 
2 lost to follow-up (censored)
8 had a PCR negative for 
Mycobacterium ulcerans
5 had a PCR negative for 
Mycobacterium ulcerans
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2­year trial. Accrual was slow, despite active case finding 
and increased site visits. Accrual was extended twice 
(March 24, 2015, and March 21, 2017) following interim 
reports during biannual meetings with the study sponsor. 
All interim reports for this open­label study showed 
similarity of efficacy outcomes between treatment 
groups, so on March 21, 2017, the study sponsor and 
stakeholders decided to end further accrual at the end 
of 2017. 443 patients were assessed for eligibility, and 
accrual ended with 310 participants, 297 of whom had 
PCR­confirmed Buruli ulcer (figure 1).
Table 1 shows that baseline characteristics of study 
participants were balanced; sex distribution was almost 
equal between groups (153 [52%] of 297 par ticipants were 
female), and median age was 14 years (IQR 10–29). Most 
lesions were on the limbs; the lower limb was affected in 
163 (55%) participants; the upper limb was affected in 
108 (37%) participants. In 156 (53%) participants, lesions 
were ulcerated at presentation.
Lesions had healed without relapse at week 52 after 
start of treatment in 144 (95%, 95% CI 91 to 98) of 
151 patients receiving RS8 compared with 140 (96%, 
91 to 99) of 146 patients receiving RC8. The difference in 
proportion of patients with healed lesions, –0·5 (95% CI 
–5·2 to 4·2), was not significantly greater than zero 
(p=0·59). The upper limit of the 95% CI of the difference 
of 4·2% is less than the non­inferiority margin of 12%, 
showing non­inferiority.
Time to healing was a secondary endpoint. Figure 2 
shows the plot of cumulative probability of healing with 
95% CIs and the results of Cox proportional hazard for 
time to healing. The median time to healing was 24 weeks 
(IQR 8–28) in the RS8 group, and 16 weeks (IQR 8–25) 
in the RC8 group. There were no recurrences and treat­
ment failure rates were similar within 12 months of 
treatment. Treat ment was unsuccessful for six patients 
receiving RC8 and for seven patients receiving RS8. The 
incidences of paradoxical response were not statis tically 
different between study groups. If a paradoxical response 
was defined as an increase in lesion surface area by more 
than 20% compared with a previous measurement, 
after initial reduction in lesion size,27 the incidence was 
34% in the RC8 group and 43% in the RS8 group 
(p=0·093). If other definitions were used, the difference 
remained non­significant. Further details are provided in 
the appendix (p 4). In the RS8 group, lesion healing in 
category I (<5 cm) lesions took a median of 16 weeks 
(IQR 6–28) compared with 28 weeks (16–38; p<0·0001). 
In the RC8 group, category I lesions healed at a median 
of 13 weeks (IQR 6–24) compared with 20 weeks (12–32) 
in category II (p=0·031; see appendix pp 5–6). Lesion 
type (ulcer, compared with non­ulcerated lesions at pre­
sentation: nodule, plaque, or oedema) did not influence 
time to healing. In the RS8 group, ulcers healed at a 
median of 20 weeks (IQR 8–28) versus 24 weeks (6–35) 
in non­ulcerated lesions (p=0·31). In the RC8 group, 
ulcers healed at a median of 12 weeks (IQR 8–24), while 
non­ulcerated lesions were healed at a median of 
20 weeks (8–25; p=0·60; appendix p 8). Additional 
surgery consisted only of skin grafting, and this was 
necessary in four (1%) study participants (two in the RC8 
group and two in the RS8 group), all of whom had 
category II lesions. All grafts were done after week 14. 
There were no residual functional limitations at week 52 
following antimicrobial treatment. The compliance rates 
were 100% in all patients given RC8 and RS8 regi­
mens. Using a threshold increase of more than 25 dB, 
three (2%) participants in the RS8 group had hearing 
loss compared with one (1%) in the RC8 group. In 
the RS8 group, five (3%) participants experienced 
dizziness with or without accompanying imbalance or 
tinnitus, versus none in the RC8 group. Taken together, 
otovestibular toxicity occurred in eight (5%) individuals 
in the RS8 group compared with one (1%) in the RC8 
RS8 (n=151) RC8 (n=146) Total (n=297)
Sex
Male 74 (49%) 70 (48%) 144 (49%)
Female 77 (51%) 76 (52%) 153 (52%)
Age, years
Mean 20·4 (16·3) 22·9 (17·7) 21·6 (17·0)
Median 14 (10–25) 16 (10–32) 14 (10–29)
Education level
None 35 (24%) 43 (30%) 78 (27%)
Primary or middle 
school
100 (67%) 92 (64%) 192 (66%)
Secondary school 
or above
14 (9%) 8 (6%) 22 (8%)
Weight, kg
Mean 41·5 (15·9) 43·0 (17·5) 42·3 (16·7)
Median 41 (27–55) 44 (26–58) 42 (26–57)
Height, m
Mean 1·5 (0·2) 1·5 (0·2) 1·5 (0·2)
Median 1·5 (1·3–1·6) 1·5 (1·3–1·6) 1·5 (1·3–1·6)
Lesion location
Upper limb 47 (31%) 61 (42%) 108 (37%)
Lower limb 90 (60%) 73 (50%) 163 (55%)
Buttocks and 
perineum
3 (2%) 1 (1%) 4 (1%)
Head and neck 1 (1%) 4 (3%) 5 (2%)
Thorax 4 (3%) 3 (2%) 7 (2%)
Abdomen 2 (1%) 3 (2%) 5 (2%)
Back 3 (2%) 1 (1%) 4 (1%)
Lesion type
Nodule 28 (19%) 34 (23%) 62 (21%)
Plaque 39 (26%) 36 (25%) 75 (25%)
Oedema 1 (1%) 3 (2%) 4 (1%)
Ulcer 83 (55%) 73 (50%) 156 (53%)
Data are n (%), mean (SD), or median (IQR). RC8=oral rifampicin 10 mg/kg plus 
clarithromycin 15 mg/kg extended release once daily for 8 weeks. RS8=oral 
rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 
8 weeks.
Table 1: Baseline characteristics
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group. One (1%) participant in the RS8 group had to 
discontinue allocated treatment after week 6 (table 2). 
No renal damage was detected in blood chemistry tests. 
Few participants had electrocardiogram changes, which 
were similar in both study groups (four [3%] in the 
RS8 group and three [2%] in the RC8 group). Gastro­
intestinal and mucocutaneous adverse events were few 
and equally distributed. No neurological events were 
noted. Mild (grade 1–2) laboratory abnormalities were 
fairly common in both study groups; the proportion 
appeared largest at baseline.
The 13 study participants whose treatment was unsuc­
cessful (seven [5%] in the RC8 group and six [4%] in the 
RS8 group) are summarised in the appendix (p 8). 
Ten (3%) participants with lesions that did not heal by 
week 52 had category II lesions. Seven of the patients 
whose treatment was unsuccessful were actually lost to 
follow­up: two went on to heal after 52 weeks, one had 
osteomyelitis, two had non­healed lesions at the lateral 
malleolus where recur rent trauma was suspected as 
a cause of non­healing, malig nancy was suspected in 
one participant, and none were suspected to have ongoing 
M ulcerans infection.
Just one participant dropped out of the study. One 
participant in the RC8 group had detected pregnancy at 
week 6, but she continued in the allocated treatment. 
Six participants were lost to follow­up at some point in 
time after completion of drug treatment. The censored 
data could still be used for analysis of these participants, 
and adher ence to drug treatment was high in both study 
groups. No recurrences were noted during follow­up.
Discussion
With these findings, we provide evidence that a fully oral 
antimicrobial treatment for early, limited Buruli ulcer 
with rifampicin and an extended release formulation of 
clarithromycin (RC8) is non­inferior to the treat ment 
with rifampicin and injected streptomycin (RS8). 
Although both treatments were generally well tolerated, 
safety outcomes were in favour of fully oral treatment 
with RC8. Eight individuals receiving streptomycin had 
side­effects attributed to the drug. Our results support 
the use of fully oral treatment with RC8 as first­line 
treatment for early, limited Buruli ulcer lesions. Oral 
treatment is far more convenient for patients and also 
prevents the toxicity (predominantly acoustic and 
vestibular) that can occur with the use of the injectable 
aminoglycoside streptomycin.16 This study addressed a 
question that was also deemed important by former 
patients who prioritised research into treatment that 
avoided painful injections and had few side­effects.28 
Age and sex distribution, as well as socioeconomic status 
and educational level in this study population were all 
typical for the population affected by Buruli ulcer in west 
Africa.
Our study had limitations, the most important being 
the open­label design. Concealment of active study 
Figure 2: Cumulative probability of a Buruli ulcer lesion healing over time
95% CIs are shown. Lesion healing was defined by full epithelialisation or stable scar. HR=hazard ratio. RC8=oral 
rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks. RS8=oral rifampicin 
10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks.
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RS8 
(n=151)
RC8 
(n=146)
Total 
(n=297)
Any adverse event 20 (13%) 9 (6%) 29 (10%)
Serious adverse event* 1 (1%) 0 1 (<1%)
Adverse event, not serious 19 (13%) 9 (6%) 29 (10%)
Otovestibular toxicity 8 (5%) 1 (1%) 9 (3%)
Ototoxicity, >25 dB hearing loss 3 (2%) 1 (1%) 4 (1%)
Vestibular toxicity 5 (3%) 0 5 (2%)
Mucocutaneous manifestations 3 (2%) 0 3 (1%)
Skin rash (grades 1–2 only) 2 (1%) 0 2 (1%)
Conjunctivitis 1 (1%) 0 1 (<1%)
Constitutional symptoms 1 (1%) 0 1 (<1%)
Fever 1 (1%) 0 1 (<1%)
Headache 1 (1%) 2 (1%) 3 (1%)
Malaise 0 1 (1%) 1 (<1%)
Lymphadenopathy 1 (1%) 1 (1%) 2 (1%)
Cough 0 1 (1%) 1 (<1%)
Gastrointestinal 2 (1%) 0 2 (1%)
Nausea and vomiting 1 (1%) 0 1 (<1%)
Abdominal pain 1 (1%) 0 1 (<1%)
Confusion 0 0 0
ECG changes 4 (3%) 3 (2%) 7 (2%)
QTc prolongation (but <490 msec) 3 (2%) 2 (1%) 5 (2%)
Other (down-slope ST, P wave 
increase)
1 (1%) 1 (1%) 2 (1%)
Data are n (%). RC8=oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended 
release once daily for 8 weeks. RS8=oral rifampicin 10 mg/kg plus intramuscular 
streptomycin 15 mg/kg once daily for 8 weeks. ECG=electrocardiogram. *Older 
patient with hearing loss, dizziness, and imbalance leading to discontinuation at 
week 6.
Table 2: Summary of adverse drug reactions
Articles
www.thelancet.com   Published online March 12, 2020   https://doi.org/10.1016/S0140-6736(20)30047-7 7
medication was not considered appropriate as it would 
not have been appropriate to give children a placebo 
injection. We were unable to fully rule out bias in the 
judgments by the inves tigators of the primary endpoint 
(ie, healing at week 52) and the secondary endpoint 
(time to healing). Assessments were, however, made by 
attending team members, and all staff involved in the 
study had formal training in good clinical practice. 
Monitoring and digital photographic documentation at 
follow­up helped reach consensus in determining the 
primary endpoint of healing. We explored any potential 
bias by assessing healing by a panel of wound experts 
masked to treat ment allocation, and we were unable to 
detect bias in the reading of the imaging. Occasional 
shortages in dressing materials were infrequent, and we 
believe that these randomly occurring events did not 
influence the data, with block randomisation applied in 
each study site. Most materials could still be purchased 
on the local market if stock­outs occurred, with the 
exception of short­stretched bandage.
Although this study is the largest treatment trial for 
Buruli ulcer disease to date, our study did not reach the 
initially intended sample size of 332 participants with 
PCR­confirmed Buruli ulcer. The duration of the study 
had already been extended twice, and it was decided to 
stop accrual based on an ad­hoc interim analysis 
suggesting that extending the study any further would 
not result in different study outcomes. Since the start of 
the study, with declining numbers of recorded patients 
with new Buruli ulcer, the number of patients steadily 
declined at the study sites, a phe nomenon that has been 
observed in most west African endemic regions.6,29,30 The 
incidence of Buruli ulcer has fluctuated and has recently 
emerged, unprecedentedly, in Victoria, Australia.4,5,8,9 
Another limitation was that we are unable to address the 
efficacy of RC8 on larger Buruli ulcers (ie, larger than 
10 cm), which were excluded.
Several aspects in the experimental design aided in 
producing a high­quality study in terms of level of care 
provided for other aspects than the drug treatment alone. 
These included a focus on wound care, rehabilitation, 
and pain management during dressing changes. 
However, despite these measures, the median time to 
wound healing was similar to that reported in previous 
studies.14,15,19
The strengths of the study were the large sample size, 
the diagnostic confirmation by validated PCR technology, 
extended monitoring and auditing, the high healing rate 
at week 52, the very low drop­out rate, and minimal loss 
to follow­up. We used internet­based data storage and 
data collection, and we used a web­based platform for 
intensive interactions and consultations within the study 
team. Very few study participants needed any form of 
surgery. No debridement surgery was done in any of the 
study participants, and only four patients had skin grafts. 
This is consistent with findings from a study in Benin 
addressing the role of surgery in Buruli ulcer disease.31
The RC8 treatment had excellent tolerability and 
efficacy, and our findings support data from Benin20 and 
Australia.32,33 During screening, seven patients were 
excluded because of pregnancy. Although we counselled 
study participants to prevent pregnancy during the first 
8 weeks of the study, one participant in the RC8 group 
had a positive pregnancy test at week 6. Although clarith­
romycin is not listed as safe for use during pregancy, 
we considered this drug combination relatively safe as it 
has been used frequently without reported ill effects, and 
she decided to complete her allocated treatment. Under 
service conditions, pregnancy tests are not routinely 
done, and we suspect a considerable risk of intrauterine 
streptomycin exposure, which would be prevented if oral 
RC8 treatment becomes the standard of treatment.
In real­world settings, daily drug treatment for 8 weeks 
in combination with regular wound dressing changes 
remains challenging in the rural endemic setting in 
west and central Africa. Not all patients necessarily need 
a full course of 8 weeks of antimicrobial treatment,34,35 but 
how much treatment would suffice is unknown, and 
individualised treatment duration for Buruli ulcer has 
not been evaluated in a randomised trial. Drug–drug 
interactions between rifampicin and clarithromycin 
result in reduced expo sure to clarithromycin within 
2–3 weeks, as a result of hepatic enzyme induction by 
rifampicin,36 and perhaps the most important action of 
clarithromycin at onset of treatment is the prevention of 
clonal expansion of M ulcerans with reduced susceptibility 
to rifampicin.37 This phenomenon, however, appears 
uncommon,38 but surveillance for rpoB mutations in 
clinical isolates of M ulcerans would be helpful. Con­
sidering that the role of clarithromycin is primarily a 
companion drug, we suspect that providing this drug as a 
once­daily extended release preparation had no marked 
effect on overall efficacy. At the time of designing the 
study, and based on the limited exposure of the imme­
diate release preparation of clarithromycin 7·5 mg/kg,36 
we decided to double the dose in this extended release 
form.
Experimental treatments with shorter duration are 
under investigation,39–41 but novel drugs usually take a 
considerable time to reach the clinical arena. Our study 
provides evidence that this combination of oral generic 
rifampicin and extended release clarithromycin provides 
excellent tolerability and efficacy.
On the basis of its non­inferiority compared with 
streptomycin plus rifampicin (RS8), we recommend the 
combination of oral rifampicin and clarithromycin 
(RC8) for patients with Buruli ulcer lesions. We only 
provide evidence for this recommendation for lesions of 
limited size, in individuals aged 5 years and older. This 
oral antimicrobial treatment might also be beneficial for 
patients with larger lesions, and for younger patients.
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